BioTissue’s Regenerative Healing Advancements Featured at 2025 Big Sky Sports Medicine Conference

Clinical Study Supports the Effectiveness of Clarix® Flo for Muscle and Ligament Tears

MIAMI, January 27, 2025—New research will be showcased this week at the 2025 Big Sky Sports Medicine Conference (BSSMC) in Big Sky, Montana, highlighting BioTissue’s Clarix® Flo, a micronized Amniotic Membrane (AM), for muscle and ligament tears. A pioneer in the application of cryopreserved human birth tissue products, BioTissue specializes in regenerative healing for chronic wounds, musculoskeletal conditions, and ocular surface diseases and disorders.

“This research highlights our commitment to advancing sports medicine through innovative clinical studies that leverage the unique regenerative potential of amniotic tissue,” said BioTissue CEO Ted Davis. “In sports, we understand the importance of recovering quickly and returning to peak performance. We’re excited to provide athletes and their care teams with a safe, effective solution to get back in the game faster.”

The study reviewed collegiate football players who received micronized AM for muscle or ligament tears. Athletes with injuries like medial collateral ligament tears and hamstring strains returned to play an average of 29.6 days post-treatment, with 80% returning within four weeks. No complications or re-injuries were reported, demonstrating the potential safety and effectiveness of AM injections in supporting recovery.

In addition to unveiling new research, BioTissue is hosting a case discussion titled The Race to Regenerative Healing – Human Birth Tissue: When and Where? The session, led by Dr. Robert Anderson of OrthoCarolina Foot & Ankle Institute in Charlotte, N.C., and Dr. Jason Krystofiak of RWJBarnabas Health in Livingston, N.J., will explore strategies for achieving optimal outcomes in patient care. The session will take place on Wednesday, January 29, at 3:00 p.m. MDT.

“Our goal isn’t just to treat injuries, but to change the way we think about healing – we’re proud to pave the way for innovative solutions that help athletes perform at their best,” said Davis.

For more information on BioTissue and Clarix® Flo, visit BioTissue.com/surgical.

# # #

About BioTissue Holdings Inc.

BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of Cryopreserved Amniotic Membrane (CAM) products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 900,000 human implants with its products and published over 400 peer-reviewed publications supporting BioTissue’s platform technology. Learn more at biotissue.com.

Media Contact

Laura DiCaprio

McDougall Communications for BioTissue Holdings Inc.

[email protected] or (585) 434-2153